← Back to Stock Screener← Stock Screener

ZYBERNO

Stock Report

Updated Aug 31, 2026

ZEPP HEALTH CORP (ZEPP)

Technology • NYSE

$4.82

Professional Investment Analysis

ZYBERNO SCORE →

Is it a great business? Is it getting better?

12.0/100

POOR BUSINESS

ZEPP HEALTH CORP (ZEPP) scores 12/100 — concerning metrics indicating significant structural or financial risks.

📊 How is the Zyberno Score calculated? +

The Zyberno Score answers one question: "Is this a quality business worth owning?" It's a 0-100 investment grade that evaluates business fundamentals across four critical dimensions, based on principles from Warren Buffett, Benjamin Graham, Peter Lynch, and Charlie Munger.

The 4 Core Categories (25 points each):

1. PROFITABILITY (25 pts)

Metrics: ROE, ROIC, Net Margin, Operating Margin
Thresholds: ROE >20% excellent • ROIC >20% excellent • Net Margin >20% excellent • Operating Margin >25% excellent

2. FINANCIAL STRENGTH (25 pts)

Metrics: Debt-to-Equity, Current Ratio, Interest Coverage, Altman Z-Score
Thresholds: D/E <0.3 excellent • Current Ratio >2.5 excellent • Interest Coverage >10x excellent • Altman Z >3.0 safe

3. CASH FLOW QUALITY (25 pts)

Metrics: Free Cash Flow, OCF vs Net Income, FCF Margin
Thresholds: Positive & growing FCF excellent • OCF/NI >1.2x excellent (cash earnings exceed accounting)

4. GROWTH & CONSISTENCY (25 pts)

Metrics: Revenue Growth, Net Income Growth, FCF Growth, Piotroski F-Score
Thresholds: Growth via log-linear regression • Piotroski 8-9 excellent, 6-7 good

Score Interpretation:

75-100

GREAT BUSINESS

65-74

GOOD BUSINESS

50-64

AVERAGE BUSINESS

30-49

WEAK BUSINESS

0-29

POOR BUSINESS

→ View full ZEPP quality analysis & detailed breakdown

VALUATION SIGNAL

N/A (Requires more data)

Requires fair value calculation and current price data

💰 How is Margin of Safety calculated? +

Margin of Safety measures how much discount or premium you're paying relative to a stock's intrinsic value. It's Benjamin Graham's core principle: the larger the margin, the lower your downside risk.

Formula: (Intrinsic Value − Current Price) ÷ Intrinsic Value × 100%

How We Calculate Intrinsic Value (DCF Method):

Step 1: Calculate current Owner Earnings (OCF − Maintenance CapEx)

Step 2: Calculate company-specific growth rate using log-linear regression on 16 quarters of Owner Earnings

Step 3: Project 10 years forward using the calculated growth rate

Step 4: Discount each year's cash flow to present value using 10% discount rate

Step 5: Calculate terminal value using 3% perpetual growth rate

Step 6: Sum all discounted cash flows = Intrinsic Value

What The Percentages Mean:

+50% or more

EXCELLENT — Very undervalued

+25% to +50%

GOOD — Attractive discount

0% to +25%

FAIR — Reasonable value

0% to -25%

CAUTION — Slight premium

-25% or worse

POOR — Overvalued

"Price is what you pay, value is what you get." — Warren Buffett

→ View full ZEPP valuation analysis · → View full ZEPP Brina Gap analysis

📈 How is Brina Gap calculated? +

Brina Gap measures the difference between the growth a business can fundamentally sustain and the growth the market is already pricing in.

Formula: Fundamental Growth Rate − Market-Implied Growth Rate

The Two Components:

Fundamental Growth Rate = ROIC × Reinvestment Rate

What the business can sustainably grow at based on how much it reinvests and what return it earns on that capital. Grounded in historical financials.

Market-Implied Growth Rate = Reverse DCF

The growth rate the current Enterprise Value implicitly assumes. Calculated by back-solving a 10-year DCF model (10% WACC, 3% terminal growth) until the present value of projected cash flows equals EV.

What The Gap Means:

Gap > +5% Market Underestimates — potential upside

+2% to +5% Slight Underestimate

-2% to +2% Fairly Priced — market consensus matches fundamentals

-5% to -2% Slight Overestimate

Gap < -5% Market Overestimates — price embeds optimism fundamentals don't support

A positive gap (market underestimates) combined with a positive Margin of Safety is the strongest combined signal — the business is both cheap historically and forward economics are stronger than the price suggests.

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)

Debt-to-Equity (Solvency Risk):EXCELLENT (0.29x)

Operating Margin (Operational Efficiency):CRITICAL (0.0%)

Return on Capital (Capital Efficiency):CRITICAL (-10.1%)

📊 Valuation Trilogy

Three interconnected metrics for complete valuation analysis

Click any metric for full methodology and detailed analysis

Zyberno's Verdict

ZEPP HEALTH CORP (ZEPP) stock report — Zyberno Score 12/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY

A. Market Valuation

Market Price & Capitalization (2)

Current Price:4.82

Market Cap:$66.44M

Valuation Multiples (3)

P/B Ratio:0.31x

P/S Ratio:0.26x

Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$69.80M

Price Action & Momentum (1)

% of 52-Week High:7.8%

B. Profitability Assessment

Return Metrics (3)

Roic:

-10.1%

📊 Click to view full ZEPP ROIC analysis →

Reinvestment Rate:2.2%

Fundamental Growth Rate (g):-0.2%

Margin Analysis (1)

Ebitda Margin:-10.6%

Yield Metrics (2)

Earnings Yield:-$999.00

Dividend Yield:8.0%

C. Log-Linear Regression Growth Trends

D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.02x

Quick Ratio:0.77x

Cash Ratio:0.20x

Leverage Analysis (3)

Debt To Equity Ttm:0.29x

Debt-to-Equity Ratio:0.29x

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-5.13x

Times Interest Earned:-5.13

Capital Structure (4)

Working Capital:6,681,000.00

Cash And Cash Equivalents:57,046,000.00

Long Term Debt:$59.48M

Net Debt:$3.36M

DIVISION II: FINANCIAL STATEMENTS ANALYSIS

A. Income Statement Analysis

Revenue Components (2)

$258.90M

Cost Of Revenue Ttm:$159.71M

Profitability Breakdown (2)

$99.19M-$29.23M

Bottom Line Performance (3)

-$40.07M

Income Before Tax:-$35.46M

Ebitda Ttm:-27,520,000.00

Operating Expenses (5)

Operating Expenses:128,420,000.00

R And D Expense:45,318,000.00

Sga Expense:29,273,000.00

Income Tax Expense:$2.54M

Interest Expense:5,697,000.00

Expense Ratios (3)

R And D To Revenue Percentage:17.5%

Sga To Revenue Percentage:11.3%

Ebitda Margin:-10.6%

B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$564.84M

Current Assets:$293.53M

Ppe Net:5,662,000.00

Goodwill:9,581,000.00

Intangible Assets:$13.61M

Liability Structure (4)

Total Liabilities:350,303,000.00

Current Liabilities:286,844,000.00

Long Term Debt:$59.48M

Short Term Debt:$930.00K

Equity & Capital (3)

Equity:$214.53M

Retained Earnings:-$11.45M

Common Stock:405,462,685.00

Working Capital Items (3)

Accounts Receivable:66,908,000.00

Inventory:72,756,000.00

Accounts Payable:80,768,000.00

Special Items (2)

Contract Liabilities:4,664,000.00

Stock Based Compensation:2,492,000.00

C. Cash Flow Analysis

Operating Activities (2)

-$25.69M-$26.21M

Investment Activities (1)

Investing Cash Flow:$1.48M

Financing Activities (3)

Financing Cash Flow:$24.84M

Dividends Paid Ttm:5,928,182.24

Stock Repurchase:1,238,000.00

Capital Transactions (3)

Common Stock Issuance:0.00

Long Term Debt Issuance:$0.00

Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:1,710,000.00

DIVISION III: OPERATIONAL METRICS

A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:-$2.91

Revenue & Cash Per Share (2)

Sales Per Share Ttm:18.78

Operating Cash Flow Per Share:-$1.86

Book Value & Capital (2)

Book Value Per Share:$15.56

Cash Per Share:4.14

Dividend Policy (1)

Dividend Payout Ratio:-999.00x

B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.46x

Working Capital Turnover Ttm:38.75x

Receivables Management (2)

Receivables Turnover Ttm:3.87x

Days Sales Outstanding Ttm:94.33

Inventory Management (2)

Inventory Turnover Ttm:2.20x

Days Inventory Outstanding Ttm:166.28

Payables & Cash Cycle (2)

Days Payable Outstanding:184.59

Cash Conversion Cycle:76.02

C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:80.00

Quality Score:35.00

Market Metrics (2)

Beta:0.00x

Volatility Category:unknown

DIVISION IV: INVESTMENT ANALYSIS

A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:2.2%

Fundamental Growth Rate (g):-0.2%

B. Log-Linear Regression Growth Analysis

C. Company Profile & Context

Corporate Information (6)

Symbol:ZEPP

Company Name:ZEPP HEALTH CORP

Sector:Technology

Industry:Computer Hardware

Exchange:NYSE

Country:United States

Market Classification (3)

Market Cap Category:N/A

Price Category:low

Volume Category:N/A

Share Structure (3)

Shares Outstanding:13.78M

Shares Outstanding Basic:254.43M

Shares Outstanding Diluted:254.43M

Data Processing Info (3)

Processing Version:v3.0

Last Updated:2026-08-31 23:42:13 UTC

Data Timestamp:2026-08-20T03:59:11.358968